Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells $2,218,500.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the sale, the chief executive officer owned 566,683 shares in the company, valued at $83,812,415.70. This represents a 2.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00.
• On Monday, August 3rd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $144.74 on Monday. The stock has a market capitalization of $179.47 billion, a price-to-earnings ratio of -54.21 and a beta of 0.31. The firm’s 50-day moving average price is $143.63 and its two-hundred day moving average price is $136.49. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1-year low of $109.66 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences’s payout ratio is presently -122.85%.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Davidson Trust Co. increased its holdings in Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 74 shares during the last quarter. Financial Connections Group Inc. grew its position in shares of Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 76 shares during the period. Wilkerson Advisory Group LLC increased its stake in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 78 shares during the last quarter. Balboa Wealth Partners raised its holdings in shares of Gilead Sciences by 2.7% in the 1st quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock valued at $426,000 after purchasing an additional 79 shares during the period. Finally, HBW Advisory Services LLC lifted its stake in Gilead Sciences by 2.4% in the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock valued at $473,000 after purchasing an additional 79 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on GILD shares. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.78.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s HIV portfolio remains the primary growth driver. Biktarvy helped lift quarterly revenue to approximately $7.8 billion, while the company’s broader revenue increased 10.6% year over year. Biktarvy Drives Gilead Sciences Revenue to $7.8 Billion
• Positive Sentiment: Barron’s reiterated a bullish view, noting that Gilead shares have risen 35% since its earlier coverage but arguing that the company’s catalysts have not yet fully played out. The view supports continued investor interest in the pipeline and core HIV business. More Upside Awaits for Gilead Sciences Stock
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth about $2.2 million. Because the transaction was executed under a pre-arranged Rule 10b5-1 plan, it may have limited bearish significance, although insider selling can weigh on sentiment. Gilead SEC Form 4 Filing
• Neutral Sentiment: Gilead has become one of the most-watched stocks among Zacks users, indicating elevated market attention but not necessarily a change in fundamentals. Gilead Trending Stock Analysis
• Negative Sentiment: Zacks Research downgraded Gilead from “strong buy” to “hold,” potentially encouraging profit-taking after the stock’s strong recent advance and reducing near-term buying support.

Gilead Sciences Company Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.